Study of the Toxic Manifestation of Etoposide the Concomitant Exposure of Acetyl Salicylic Acid As a Protector on the Example of C57Bl/6J Mice Line
https://doi.org/10.37489/0235-2990-2023-68-5-6-33-38
Abstract
The paper presents the results of evaluating the genetic and cytogenetic toxicity of etoposide, as well as the evaluation results of protective properties of aspirin against the toxicity of etoposide in C57Bl/6J mice. The cytogenetic activity and protective properties assessment was carried out using the chromosome aberration analysis in metaphase cells. Etoposide was tested at a concentration of 15 and 3 mg/kg and aspirin — at a concentration of 25 mg/kg of the animal. The results of metaphase analysis showed that etoposide exhibits cytogenetic toxicity in both doses, and aspirin exhibits protective properties against the toxicity of etoposide at a concentration of 15 mg/kg. The results of chromosome analysis regarding the protective properties of aspirin against etoposide at a concentration of 3 mg/kg are ambiguous and require further experiments.
About the Authors
O. N. AntosyukRussian Federation
Ph. D. in Biology, Associate Professor
19 Mira st,, Ural Federal University named after the first President of Russia B. N.Yeltsin, Yekaterinburg, 620002
Competing Interests:
Авторы сообщают об отсутствии конфликта интересов.
A. V. Gorskaya
Russian Federation
student
Competing Interests:
Авторы сообщают об отсутствии конфликта интересов.
D. V. Petrovskii
Russian Federation
Ph. D. in Biology, chief expert Institute of Systematics and Ecology of Animals of the Siberian Branch of the Russian Academy of Sciences
Competing Interests:
Авторы сообщают об отсутствии конфликта интересов.
T. D. Dubatolova
Russian Federation
Researcher
Competing Interests:
Авторы сообщают об отсутствии конфликта интересов.
References
1. Sandoval C., Pui C.H., Bowman L.C., Heaton D., Hurwitz C.A., Raimondi S.C. et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993; 11 (6): 1039–1045. doi: 10.1200/JCO.1993.11.6.1039.
2. Smith M.A., Rubinstein L., Ungerleider R.S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol. 1994; 23 (2): 86–98. doi: 10.1002/mpo.2950230205.
3. Sortibrán A.N.C., Tellez M.G.O., Rodriguez-Arnaiz R. Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster. Mutat Res. 2006; 604 (1–2): 83–90. doi: 10.1016/j.mrgentox.2006.01.003. Epub 2006 Mar 9
4. Turner S.D., Wijnhoven S.W., Tinwell H., Lashford L.S., Rafferty J.A., Ashby J. et al. Assays to predict the genotoxicity of the chromosomal mutagen etoposide — focussing on the best assay. Mutat Res/Genetic Toxicology and Environmental Mutagenesis. 2001; 493 (1–2): 139–147. doi: 10.1016/s1383-5718(01)00170-x.
5. Brotons C., Benamouzig R., Filipiak K.J., Limmroth V., Borghi C. A systematic review of aspirin in primary prevention: is it time for a new approach?. Am J Cardiovasc Drugs. 2015; 15 (2): 113–133. doi: 10.1007/s40256-014-0100-5.
6. Mills E.J., Wu P., Alberton M., Kanters S., Lanas A., Lester R. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med. 2012; 125 (6): 560–567. doi: 10.1016/j.amjmed.2012.01.017.
7. Rothwell P.M., Fowkes F.G.R., Belch J.F.F., Orawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377 (9759): 31–41. doi: 10.1016/S0140-6736(10)62110-1.
8. Rothwell P.M., Wilson M., Price J.P., Belch J.F.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379 (9826): 1591–1601. doi: 10.1016/S0140-6736(12)60209-8.
9. Rothwell P.M., Algra A., Chen Z., Diener H-C., Norrving B., Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016; 388 (10042): 365–375. doi: 10.1016/S0140-6736(16)30468-8.
10. Oliveira V.C., Constante S.R.C., Polloni L., Orsolin P.C., Silva-Oliveira R.G., Machado N.M. et al. Protective effect of aspirin against mitomycin C-induced carcinogenicity, assessed by the test for detection of epithelial tumor clones (warts) in Drosophila melanogaster. Drug Chem Toxicol. 2018; 41 (3): 330–337. doi: 10.1080/01480545.2017.1415926.
11. Wang H., Luo Y., Lin Z., Lee I-W., Kwon J., Cui X-S. at al. Effect of ATM and HDAC inhibition on etoposide-induced DNA damage in porcine early preimplantation embryos. PLoS One. 2015; 10 (11): 1–19. doi: 10.1371/journal.pone.0142561. eCollection 2015.
Review
For citations:
Antosyuk O.N., Gorskaya A.V., Petrovskii D.V., Dubatolova T.D. Study of the Toxic Manifestation of Etoposide the Concomitant Exposure of Acetyl Salicylic Acid As a Protector on the Example of C57Bl/6J Mice Line. Antibiot Khimioter = Antibiotics and Chemotherapy. 2023;68(5-6):33-38. (In Russ.) https://doi.org/10.37489/0235-2990-2023-68-5-6-33-38